Systemic Treatment of Advanced Pancreatic Cancer: From Established Regimens to Emerging Breakthroughs — A Narrative Review
Journal of Medical and Radiation Oncology · 10.11.2026 · 6 (1) · 5-10
DOI: 10.53011/jmro.2026.01.03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical and Radiation Oncology, online erschienen am 31.10.2026. Verfasst von Mehdi Alem und 8 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in Western countries and carries a poor 5-year survival rate of less than 10%. With only 10–20% of patients eligible for curative surgery, systemic chemotherapy remains the cornerstone of treatment for the majority. Significant therapeutic advances have been achieved over the past decade, with new regimens, novel biological agents, and innovative physical approaches now reshaping the therapeutic landscape.
Objective
This narrative review summarizes the current evidence base for the systemic treatment of locally advanced and metastatic PDAC, with a focus on clinically significant data published between 2018 and 2026. Key results. FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX remain the three validated first-line regimens for patients with good performance status (PS). The NAPOLI-3 trial established NALIRIFOX as a third first-line option with a superior median overall survival (OS 11.1 vs 9.2 months). The phase III PANOVA-3 trial demonstrated, for the first time, a significant overall survival benefit from adding tumor-treating fields (TTFields) to chemotherapy in locally advanced disease (median OS 16.2 vs 14.2 months), leading to FDA approval. Second-line treatment choice depends on the first-line regimen received: gemcitabine plus nab-paclitaxel is preferred after FOLFIRINOX or NALIRIFOX, while fluorouracil-based regimens (FOLFOX, liposomal irinotecan plus 5-FU/LV) are preferred after gemcitabine-based first-line therapy, both providing superior outcomes to gemcitabine monotherapy. For molecularly selected patients, olaparib is indicated as maintenance in germline BRCA-mutated disease, and daraxonrasib — a first-in-class RAS(ON) multi-selective inhibitor — has since demonstrated a significant overall survival benefit over chemotherapy in the phase III RASolute 302 trial in previously treated metastatic PDAC (median OS 13.2 vs 6.7 months; HR 0.40) and received FDA approval in August 2026 on this basis.
Conclusions
The PDAC treatment landscape is evolving rapidly. Patient selection based on performance status, comorbidities, and molecular profiling is paramount. The confirmed phase III survival benefit of daraxonrasib, demonstrated specifically in previously treated metastatic PDAC, represents an early proof-of-concept that targeted therapy can meaningfully change outcomes in this molecularly defined population, with first line and adjuvant trials now underway to define its broader role. Key words: pancreatic cancer; chemotherapy; FOLFIRINOX; NALIRIFOX; daraxonrasib; tumor-treating fields; targeted therapy; olaparib; KRAS
Zitieren
APA
Alem, M., Msakem, M., Abbassi, M. B., Keita, D., Amaadour, L., Oualla, K., Benbrahim, Z., Arifi, S., & Mellas, N. (2026). Systemic Treatment of Advanced Pancreatic Cancer: From Established Regimens to Emerging Breakthroughs — A Narrative Review. Journal of Medical and Radiation Oncology, 6(1), 5-10. https://doi.org/10.53011/jmro.2026.01.03
Vancouver
Alem M, Msakem M, Abbassi MB, Keita D, Amaadour L, Oualla K, et al. Systemic Treatment of Advanced Pancreatic Cancer: From Established Regimens to Emerging Breakthroughs — A Narrative Review. Journal of Medical and Radiation Oncology. 2026;6(1):5-10. doi:10.53011/jmro.2026.01.03
BibTeX
@article{Alem2026,
author = {Alem, Mehdi and Msakem, Maryam and Abbassi, Mounir Belcadi and Keita, Diango and Amaadour, Lamiae and Oualla, Karima and Benbrahim, Zineb and Arifi, Samia and Mellas, Nawfel},
title = {Systemic Treatment of Advanced Pancreatic Cancer: From Established Regimens to Emerging Breakthroughs — A Narrative Review},
journal = {Journal of Medical and Radiation Oncology},
year = {2026},
volume = {6},
number = {1},
pages = {5--10},
doi = {10.53011/jmro.2026.01.03}
}
EUVIMED